Name (Synonyms) | Correlation | |
---|---|---|
drug2367 | Study A Wiki | 1.00 |
drug2371 | Study D Wiki | 1.00 |
drug2370 | Study C Wiki | 1.00 |
drug2369 | Study B Wiki | 1.00 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase Ⅱ clinical trial to evaluate efficacy and safety of Pyramax in mild to moderate COVID-19 patients.
Description: * Patients who are rRT-PCR negative for COVID-19
Measure: Proportion (%) of patients with virological clearance of SARS-CoV-2 at day 7 post-dose* Time: Day 7Description: * Patients who are rRT-PCR negative for COVID-19
Measure: Proportion (%) of patients with virological clearance of SARS-CoV-2 at Day 3, 10, and 14 post-dose* Time: Day 3, 10, 14